Filing Flows

Filing Flows › Electromed (ELMD) › Q3 FY25

Electromed (ELMD) Q3 FY25 earnings results (third quarter fiscal 2025)

10-Q filed May 13, 2025

Electromed (ELMD) reported revenue of $15.7M for the third quarter fiscal 2025 (Q3 FY25), +13% from a year earlier and -4% from the quarter before. Operating margin was 13.6%, net earnings $1.9M (12.1% of revenue).

Revenue$15.7M
Year over year+13%
Quarter over quarter-4%
Operating margin13.6%
Net earnings$1.9M

Electromed, Q3 FY25: revenue $15.7M (+13% year over year), operating margin 13.6%, net earnings $1.9M, operating cash flow $2.1M. The chart follows the revenue to costs, profit and cash.

Q3 FY25AmountQ/QY/Y
Revenue$15.7M-4%+13%
Gross profit$12.2M-3%+18%
Operating profit$2.1M-16%+16%
Net earnings$1.9M-4%+27%
Operating cash flow$2.1M-34%+54%

What changed

Revenue was $15.7M in Q3 FY25, up 13% year over year and down 4% from the previous quarter.

Gross margin was 78.0%, up 3.1 points from a year earlier. Operating profit was $2.1M, a 13.6% margin (up 0.4 points year over year). Of the extra revenue versus a year earlier, 16% reached operating profit, above the 13% margin then. Operating expenses grew 18% against revenue growth of 13%. The fastest-growing cost line was Research & development (+66%). Net earnings were $1.9M, up 27% year over year. The effective tax rate was 17.1%.

Operating cash flow was $2.1M (up 54% year over year), 110% of net earnings. Non-cash charges added back $283K of depreciation and amortization and $757K of share-based compensation. Working capital and other items used $857K. Capital expenditures of −$153K left free cash flow of $2.2M.

Questions

What was Electromed's revenue in the third quarter fiscal 2025?

Electromed (ELMD) reported revenue of $15.7M for the third quarter fiscal 2025 (Q3 FY25), +13% from a year earlier and -4% from the quarter before.

Was Electromed profitable in the third quarter fiscal 2025?

Operating profit was $2.1M (13.6% of revenue) and net earnings $1.9M.

Open the interactive Sankey →

Source: Electromed 10-Q on SEC EDGAR.